Align Technology (ALGN) Earnings Analysis

Align Technology (ALGN) delivered mixed results in FY2026 on revenue of $132.6B versus the $133.9B estimate (+22.9% YoY) and EPS of $0.90. Below is the full Align Technology earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.

Align Technology (ALGN) Earnings Analysis — key stats

Next earnings dateFeb 6, 2025
Latest reported quarterFY2026
Earnings verdictMixed
Revenue$132.6B (vs $133.9B est · -1.0% surprise · +22.9% YoY)
EPS$0.90 (vs $0.83 est · +8.4% surprise · -12.8% YoY)
Share price$542.01 (-3.8%)
Market cap$820.0B

What you'll find

Frequently asked questions

When is Align Technology's next earnings date?
Align Technology's (ALGN) next scheduled earnings date is Feb 6, 2025. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Align Technology (ALGN) beat or miss earnings?
In FY2026, Align Technology (ALGN) posted mixed results — revenue of $132.6B versus the $133.9B estimate (-1.0% surprise) and EPS of $0.90 versus $0.83 expected (+8.4% surprise). Magnisto decodes every Align Technology (ALGN) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Align Technology (ALGN) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Align Technology (ALGN), anchored to the current $542.01 share price, so you can weigh the bull, base and bear cases for Align Technology side by side.
Is Align Technology (ALGN) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Align Technology fits your own thesis and risk profile. This is research, not investment advice.

Related stocks

Educational research, not investment advice. Figures are illustrative and may be delayed.